NCT06345482View on ClinicalTrials.gov

A Study of MHB039A for Advanced Solid Tumor

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2028

Study Completion Date

June 1, 2029

Conditions
Advanced Solid Tumor
Interventions
DRUG

MHB039A

a bispecific antibody

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Minghui Pharmaceutical (Hangzhou) Ltd

INDUSTRY